<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792527</url>
  </required_header>
  <id_info>
    <org_study_id>L-carnitine in RA</org_study_id>
    <nct_id>NCT05792527</nct_id>
  </id_info>
  <brief_title>L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis</brief_title>
  <official_title>The Use of L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid&#xD;
      arthritis via targeting Jak/STAT pathway and TGF-β1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2023</start_date>
  <completion_date type="Anticipated">March 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in DAS-28-CRP score</measure>
    <time_frame>3 months</time_frame>
    <description>Patients will undergo clinical assessment according to DAS-28-CRP score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in Multidimensional Health Assessment Questionnaire (MDHAQ) score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in serum level of C-reactive protein (CRP)</measure>
    <time_frame>3 months</time_frame>
    <description>Blood samples will be collected at base line and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in serum level of Signal transducer and activator of transcription 3(STAT 3).</measure>
    <time_frame>3 months</time_frame>
    <description>Blood samples will be collected at base line and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in serum level of Transforming growth factor β1(TGF-β1).</measure>
    <time_frame>3 months</time_frame>
    <description>Blood samples will be collected at base line and after 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this group will include 23 patients which will receive the traditional therapy of RA for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-carnitine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this group will include 23 patients which will receive 500mg L-carnitine two times daily after meal plus the traditional therapy of RA for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>One 500 mg tablet twice daily after meals</description>
    <arm_group_label>L-carnitine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with active rheumatoid arthritis (not in remission) according to American&#xD;
             College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria&#xD;
             (9) i.e., 28 joints disease activity score (DAS-28) &gt;2.6.&#xD;
&#xD;
          -  Patients receive the conventional DMARDs&#xD;
&#xD;
          -  Both sexes.&#xD;
&#xD;
          -  Age range between 18 and 70 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with heart disease (congestive heart failure, arrhythmia, hypertension,&#xD;
             ischemic heart diseases), diabetes, active infection, other illness except rheumatoid&#xD;
             arthritis.&#xD;
&#xD;
          -  Patients with renal and hepatic dysfunction.&#xD;
&#xD;
          -  Patients receiving biological DMARDs.&#xD;
&#xD;
          -  Patients receiving oral prednisolone greater than 15 mg/day.&#xD;
&#xD;
          -  Patients with hypersensitivity to study medications.&#xD;
&#xD;
          -  Patients using antioxidants.&#xD;
&#xD;
          -  Pregnant and lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdallah A Eldisouky</last_name>
    <phone>201279142631</phone>
    <email>PG_165476@pharm.tanta.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta university</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdallah A Eldisouky</last_name>
      <phone>201279142631</phone>
      <email>PG_165476@pharm.tanta.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 19, 2023</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Abdallah Abo-Elazm Shebl Eldisouky</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

